Business
Faron Pharmaceuticals Ltd: Faron appoints new...
Faron Pharmaceuticals Ltd. has appointed Heikki Jouttijärvi as Chief Technical Officer, bringing extensive experience in biopharma manufacturing and commercial operations, most recently from Adverum Biotechnologies. This appointment is considered valuable as Faron progresses its investigational immunotherapy, bexmarilimab, towards a Phase IIb trial in HR MDS, aiming to enhance immune system response against cancer by targeting macrophage function. Disclaimer*
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"\n\n \n Faron Pharmaceuticals Ltd | Company announcement | March 26, 2026 at 09:00:00 EET\nTURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company, announces the appointment of Mr. Heikki Jouttijärvi as the Company’s Chief Technical Officer (CTO).Heikki Jouttijärvi brings decades of experience in biopharma manufacturing, supply chain management and commercial operations. Most recently, he has been the SVP of Commercial Business Operations at Adverum Biotechnologies, Inc that was acquired by Eli Lilly. Prior to that Mr. Jouttijärvi has held various global roles at Menlo Therapeutics, Inc and Santen Pharmaceutical Company, Ltd. He holds a M.Sc degree in Pharmacy from the University of Helsinki.“We are extremely happy to welcome Heikki as a part of the Faron team. His wealth of experience with commercial operations, manufacturing and supply chain management with late-stage and approved drugs is incredibly valuable for us as we progress with bexmarilimab to the announced Phase IIb trial in HR MDS”, comments Dr. Juho Jalkanen, CEO of Faron.“I am honored to join the Faron team at this exciting point in time in the development of bexmarilimab. I have been amazed by the resilience and excellent hard work done with bexmarilimab to date and I am humbled to be able to join the program at this stage. We look forward to advance the program to the benefit patients, whom deserve our ultimate commitment”, says Mr. Jouttijärvi, newly appointed CTO of Faron Pharmaceuticals.For more information, please contact:IR Partners, Finland(Media)Kare Laukkanen+358 50 553 9535 / +44 7 469 766 [email protected] Partners, US(Media) Alyssa Paldo +1 847 791-8085 [email protected] Financial Advisers LLP(Nominated Adviser and Broker)Sandy Jamieson, Jo Turner+44 (0) 207 213 0880Sisu Partners Oy(Certified Adviser on Nasdaq First North)Juha KarttunenJukka Järvelä+358 (0)40 555 4727+358 (0)50 553 8990About bexmarilimabBexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor g...